Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
04:30pm, Monday, 16'th Sep 2024
PITTSBURGH , Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its third quarter 2024 financial results on Thursday, November 7, 2024, before the open of the U.S. financial m
Viatris Announces Expiration and Results of Any and All Cash Tender Offers
07:00pm, Tuesday, 10'th Sep 2024
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that the previously announced cash tender offers (the "Any and All Tender Offers"
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
11:40am, Tuesday, 10'th Sep 2024
PITTSBURGH , Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
03:30am, Wednesday, 04'th Sep 2024
PITTSBURGH , Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Ut
Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data sho
3 Top Value Stocks to Buy Right Now
05:30am, Tuesday, 20'th Aug 2024
The S&P 500's Shiller P/E Ratio indicates an overvalued market. Value stocks may provide better returns in the current economic climate.
Why Bargain-Priced Viatris Could Deliver Strong Returns
10:57am, Thursday, 15'th Aug 2024
Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and E
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
10:30am, Friday, 09'th Aug 2024
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
01:54pm, Thursday, 08'th Aug 2024
On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
Why Viatris Stock Is Jumping Today
11:52am, Thursday, 08'th Aug 2024
Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
10:56am, Thursday, 08'th Aug 2024
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Viatris (VTRS) Q2 Earnings Surpass Estimates
09:10am, Thursday, 08'th Aug 2024
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
08:40am, Thursday, 08'th Aug 2024
Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
Viatris Reports Second Quarter Financial Results for 2024
06:59am, Thursday, 08'th Aug 2024
PITTSBURGH , Aug. 8, 2024 /PRNewswire/ -- Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Gr
Viatris Announces Second Quarter 2024 Dividend
06:59am, Tuesday, 06'th Aug 2024
PITTSBURGH , Aug. 6, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued an
